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Corporate Ethics and Governance in the       
Health Care Marketplace:   
An Introduction 
Annette E. Clark1 
 
On February 27 and 28, 2004, a distinguished group of scholars, 
practitioners, health care providers, industry representatives, and consumer 
advocates gathered at Seattle University School of Law to participate in a 
conference titled “Corporate Ethics and Governance in the Health Care 
Marketplace: An Interdisciplinary Perspective.”  This conference resulted 
from a unique collaboration between the Center on Corporations, Law & 
Society at Seattle University School of Law; the University of British 
Columbia Faculty of Law; and the Pacific Northwest Center for Health, 
Law and Policy.2  The raison d’être for the symposium was to explore the 
intersection of corporate theory and health care, with a particular focus on 
issues of health care governance and ethics in the United States and Canada.  
By applying the corporate lens to health care delivery systems, the 
participants sought to provide an intellectual framework for understanding 
such critical and timely issues as access to quality medical treatment and 
affordable prescription medicines, the conversion of hospitals and insurers 
from nonprofit to for-profit entities, and the growing problem of Medicare 
and Medicaid fraud. 
Debacles such as Enron and WorldCom provide a useful background for 
this exploration.  Scholars within the corporate arena have examined the 
events that gave rise to these scandals, and have asserted that they can best 
be understood through a careful deconstruction of corporate structure, 
governance, ethics, culture, and law.  The six articles in this symposium 
reveal the strength of corporate governance analytical tools and their 
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relevance across the full breadth of corporate health care activities—from 
the relationship between mission and action in a religiously affiliated 
hospital to bioethics decision making within the biotechnology industry, 
and from corporate governance in the Canadian health care system to 
whether a corporate ethic of care can exist within health care.  This 
symposium is but the beginning of dialogue and scholarship on the linkage 
between the critical health care issues of our day and the corporate form.  
By asking whether health care might be the next Enron, we hope to 
stimulate creative discussion and innovative solutions to ensure that it is 
not. 
 In Corporate Ethics in the Health Care Marketplace,3 Lynne Dallas 
begins the work of breaking down the corporate divide.  Building on her 
earlier scholarship,4 Professor Dallas focuses on the climate and culture 
within organizations that may lead to ethical or unethical decision making.  
Her thesis is that individuals who hold positions of leadership within an 
organization create, either explicitly or implicitly, an ethical climate and 
moral tone that sets the stage for, and determines the outcome of, individual 
decision making in the corporate setting.5  Professor Dallas explores 
contextual factors within the work environment that contribute to this 
ethical climate and emphasizes that formalistic mechanisms such as ethical 
codes of conduct are far less important than more intangible factors such as 
offering support and encouragement, modeling, rewarding ethical behavior 
and decision making, and fostering an environment that is open to 
discussing ethical issues within the corporation.6  By focusing our attention 
on the importance of corporate ethical climates and culture, Professor 
Dallas lays the foundation for the symposium articles that follow. 
 Arthur LaFrance’s piece, Merger of Religious and Public Hospitals: 
Render unto Caesar…,7 is a fascinating application of Professor Dallas’s 
thesis.  Although he would undoubtedly agree that leadership sets the moral 
and ethical tone for the organization, Professor LaFrance asks unsettling 
questions about the potential consequences of importing a private hospital’s 
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religious mission (a particular form of ethical climate) into a public hospital 
through a de facto merger between the two.8  In raising these questions, he 
suggests that a health care corporation may do everything “right” in 
Dallas’s terms—the creation of a strong ethical corporate climate that is 
based on a clearly articulated and consistently applied set of values—and 
yet negatively impact the public good.  He does this by focusing particularly 
on the issue of governance: to what extent would the Ethical and Religious 
Directives for Health Care Services promulgated by the American Catholic 
Bishops Association dictate the types of health care services that could (or 
could not) be provided by the public hospital should the merger go 
through?9  As legal counsel for a group opposing the merger, Professor 
LaFrance gives us a bird’s-eye view of the ethical and legal issues raised by 
a religiously affiliated health care institution that puts its mission into 
action.  In addition, Professor LaFrance does us a great service by going 
beyond theoretical discussions of hospital corporate governance, ethical 
climate, and mission to examine the ways in which a litigator must take 
legal theories rooted in the First Amendment in order to develop and prove 
facts supporting those legal theories.  His article shows the impact on a rural 
community and its citizens should its public hospital be taken over by a 
Catholic health care entity.  This kind of scholarship, rooted in corporate 
and constitutional theory and grounded in practice and the reality of 
people’s lives, is precisely what the legal academy needs.10 
I take a slightly different tack in Ethics2: The Ethics of Bioethics in the 
Biotechnology Industry,11 by utilizing the concept of a corporate ethical 
climate to examine whether biotechnology corporations can or should 
incorporate bioethics principles and public debate into their decision 
making regarding the use of human embryos and stem cells in research.  
Much of the bioethics literature assumes that health care decision making 
takes place at a relational level—between an individual and his or her health 
care provider—but the reality is that health care and the related 
pharmaceutical and biotechnology industries operate primarily through the 
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corporate form.  If an ethical climate is at heart the meaning attached by 
employees to organizational policies, practices, and procedures,12 how 
might a biotechnology company construct an ethical environment in which 
its researchers value and take into account bioethics theories and principles, 
as well as public views, on controversial issues such as the use of human 
embryos and stem cells in for-profit research?  The private ethics advisory 
board is one such mechanism that I use as a springboard for discussing the 
benefits and problems associated with importing bioethics into the corporate 
boardroom.13  The central question in my article—whether the use of 
private ethics consultation is either a genuine corporate effort to bring 
societal values and concerns to bear on contested areas of scientific research 
or an attempt to co-opt bioethicists in the pursuit of corporate profits—is a 
microcosm of a much larger question: whether private, for-profit health care 
entities have any responsibility to society or the public good that goes 
beyond maximizing financial return on investment. 
Providing a highly informative comparative viewpoint, Janis Sarra in 
Contemporary Corporate Theory Applied to the Health Care Sector: A 
Canadian Perspective14 essentially turns on its head the question of whether 
for-profit health care entities have a social responsibility.  Because the goal 
of the Canadian health care system is universal access to essential health 
care services (i.e., the public good), Canada publicly funds most health care 
services, which are provided primarily by not-for-profit entities.15  Although 
this structure substantially limits profit-maximizing behavior that might 
harm the public’s interest in obtaining services, it raises governance and 
accountability issues precisely because the private market is not operating.  
According to Dr. Sarra, whether the health care system in question is public, 
private, or something in-between, in a world of scarce resources, we can 
find common ground in the need for effective governance.16  She identifies 
disclosure of information, oversight, and accountability as the principal 
determinants of effective governance, and she details how these challenges 
differ in the contrasting American and Canadian health care systems.17  By 
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the conclusion of Dr. Sarra’s article, the reader is left with a sense of the 
push-pull between competing models for the delivery of health care 
services; each is far from perfect, and both must operate within the reality of 
limited resources and seemingly unlimited health care needs. 
Kimberly Baker and Arissa Peterson pick up the corporate governance 
thread in Post-Caremark Implications for Health Care Organization Boards 
of Directors.18  Their article focuses on the duty of care in the wake of the 
Caremark decision, the demise of Enron, and the passage of the Sarbanes-
Oxley Act.  As health law practitioners, the authors are uniquely situated to 
sound the warning that the duty of care owed to a health care organization 
by its board of directors will come under increasing scrutiny as government 
expands its efforts to root out health care industry fraud and abuse.19  In 
reviewing the recent case law on the duty of care in the context of alleged 
illegal corporate acts, Baker and Peterson caution that the potential clearly 
exists for individual director liability for failure to act to prevent, or to at 
least identify and put a stop to, corporate health care fraud.20  Furthermore, 
the passage of the Sarbanes-Oxley Act, which applies to publicly held 
companies, has added another layer of board responsibility, including 
reporting obligations, protecting whistleblowers, and the possibility of 
criminal liability for failure to comply.  After describing the perilous legal 
environment that confronts health care boards of directors today, the authors 
detail the necessary elements of an individually tailored corporate-
compliance program aimed at reducing health care fraud and abuse.21  Their 
expert advice on implementing and maintaining corporate compliance is 
remarkably congruent with Professor Dallas’s description of the guidance 
and monitoring factors essential to the creation and maintenance of an 
ethical corporate climate.22 
The final article in this symposium, A Corporate Ethic of ‘Care’ in 
Health Care,23 authored by Professor Mark Hall, is an ideal bookend to 
Lynne Dallas’s introductory piece.  Hall takes on the philosophical, almost 
existential, question of whether a health care entity can really care about the 
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individuals that it serves; he concretizes it by examining the means a health 
care corporation might use to promote a “caring culture.”24  He looks to 
profit status, ethical codes, compliance programs, and market competition 
on the basis of a reputation for caring.  Professor Hall concludes that in 
order to promote a genuine ethic of caring, we must develop mechanisms to 
measure caring.  So central, so important, and yet so elusive is the concept 
of care.  Professor Hall’s article reminds us that in this age of corporate 
delivery of health care services, we must not lose sight of the “care” in 
health care, which brings us full circle to Dallas’s thesis that this can best be 
accomplished by the deliberate and intentional creation of an ethical 
corporate climate in which care is a core value. 
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